Ann Pain Med | Volume 1, Issue 1 | Review Article | Open Access

Monoclonal CGRP Ligand/Receptor Antibodies for the Preventive Treatment of Episodic and Chronic Migraine

Egilius LH Spierings^*

Department of Neurology, Tufts Medical Center, Tufts University School of Medicine, Boston, USA

^*Correspondance to: Egilius LH Spierings 

Fulltext PDF

Abstract

Four monoclonal antibodies are currently in development for the preventive treatment of episodic and chronic migraine, one of them against the CGRP receptor and three against the CGRP ligand. These four antibodies are, in order of development, galcanezumab, eptinezumab, fremanezumab, and erenumab, the first three against the CGRP ligand and the last one against the CGRP receptor. Published, phase II, randomized, double-blind, placebo-controlled studies suggest similar efficacy of the antibodies. Tolerability in terms of adverse-event occurrence appears good while long-term safety of CGRP blockade needs further investigation.

Keywords:

CGRP; CGRP Ligand; CGRP Receptor; Monoclonal Antibodies; Episodic Migraine; Chronic Migraine; Preventive Treatment; Eptinezumab; Erenumab; Fremanezumab; Galcanezumab; Onabotulinumtoxin A

Citation:

Spierings ELH. Monoclonal CGRP Ligand/Receptor Antibodies for the Preventive Treatment of Episodic and Chronic Migraine. Annals Pain Med. 2018;1(1):1005.